Charge Enterprises July 2021 Shareholder Letter
NEW YORK, NY / ACCESSWIRE / July 29, 2021 / Charge Enterprises Inc. (OTC PINK:CRGE),…
NEW YORK, NY / ACCESSWIRE / July 29, 2021 / Charge Enterprises Inc. (OTC PINK:CRGE),…
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD…
TORONTO, ON / ACCESSWIRE / July 29, 2021 / Anaconda Mining Inc. (“Anaconda” or the…
EDMONTON, AB / ACCESSWIRE / July 29, 2021 / OneSoft Solutions Inc. (TSXV:OSS)(OTCQB:OSSIF) (the “Company”…
VANCOUVER, BC / ACCESSWIRE / July 29, 2021 / Medaro Mining Corp. (CSE:MEDA) (“Medaro” or…
LOUISVILLE, KY / ACCESSWIRE / July 29, 2021 / Charah® Solutions, Inc. (NYSE:CHRA) (“Charah Solutions”…
THUNDER BAY, ON / ACCESSWIRE / July 29, 2021 / Wolfden Resources Corporation (TSXV:WLF) (“Wolfden“…
SatADSL now offers unique pre-paid vouchers for leisure market and access to high-end professional connectivity…
Zylpha Earns Respect From Its Bundling Performance At Simpkins & Co Solicitors Simpkins & Co…
illumr removes bias in AI for financial services organisations Damian Sutcliffe, the former EMEA CIO…
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI Viviane…
Paris, July 29, 2021 Sales growth accelerated – Full-year guidance raised Q2 2021 sales grew…
Basel, Switzerland, July 29, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S….
Across four phase III studies, approximately half of patients receiving faricimab could extend treatment time…
IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022…
FIREFISH Part 2 study showed treatment with Evrysdi helped babies stay free of permanent ventilation,…
Saint-Herblain (France), July 29, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty…
– Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod;…
Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step…